AstraZeneca

Alnylam Pharmaceuticals has joined the Alliance for Genomic Discovery as the ninth member, gaining access to a comprehensive clinical genomic database containing 250,000 whole-genomes to accelerate RNA interference therapeutic development.

Marengo Therapeutics has completed the Phase 1b safety run-in of its STARt-002 trial and determined the recommended Phase 2 dose for invikafusp alfa combined with Trodelvy in metastatic breast cancer patients.

The FDA has approved an updated label for AIRSUPRA (albuterol/budesonide) that includes evidence from the BATURA Phase IIIb trial demonstrating a 46% reduction in severe asthma exacerbations compared to albuterol alone in mild asthma patients.

AstraZeneca's subcutaneous formulation of Saphnelo (anifrolumab) demonstrated statistically significant and clinically meaningful reduction in disease activity compared to placebo in the Phase III TULIP-SC trial for systemic lupus erythematosus.

Innate Pharma received FDA Breakthrough Therapy Designation for lacutamab in Sézary syndrome and is nearing completion of Phase 3 trial protocol preparation following regulatory discussions.

AllRock Bio raised $50 million in Series A funding co-led by Versant Ventures and Westlake BioPartners to advance ROC-101, a first-in-class oral pan-ROCK inhibitor exclusively licensed from Sanofi.

NICE has recommended durvalumab (Imfinzi) for adults with limited-stage small cell lung cancer whose disease has not progressed after initial treatment, marking the first therapeutic advancement in over 30 years.

Dianthus Therapeutics' claseprubart demonstrated statistically significant and clinically meaningful improvements compared to placebo in a Phase 2 trial for generalized myasthenia gravis.

HUTCHMED will present updated clinical data for savolitinib, a selective MET tyrosine kinase inhibitor, at the 2025 World Conference on Lung Cancer, including results from SACHI, SAVANNAH, and Phase IIIb studies in non-small cell lung cancer patients.

Artelo Biosciences announced positive interim Phase 2 results for ART27.13, showing a 6.38% mean weight gain at 12 weeks versus 5.42% weight loss on placebo in cancer cachexia patients.